Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial
Merrill J, Guthridge J, Smith M, June J, Koumpouras F, Machua W, Askanase A, Khosroshahi A, Sheikh S, Rathi G, Burington B, Foster P, Matijevic M, Arora S, Wang X, Gao M, Wax S, James J, Zack D. Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial. Arthritis & Rheumatology 2023, 75: 2185-2194. PMID: 37459248, DOI: 10.1002/art.42652.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusLoss of improvementPrimary endpointLupus erythematosusWeek 32B cellsEfficacy-evaluable populationImproved disease activityPhase 2 trialProportion of patientsTreatment-related toxicityTreatment of patientsPlacebo-ControlledCorticosteroid injectionDisease activityInfusion reactionsTrough concentrationsPatient subsetsPlasma cellsPatientsSecondary analysisMonoclonal antibodiesStatistical significanceEndpointPlacebo
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply